| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
C.Q. Pharmaceutical Holding Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.66 |
| 52 Week High | CN¥6.32 |
| 52 Week Low | CN¥4.28 |
| Beta | 0.41 |
| 11 Month Change | -1.74% |
| 3 Month Change | 17.92% |
| 1 Year Change | 8.02% |
| 33 Year Change | 19.41% |
| 5 Year Change | 1.98% |
| Change since IPO | 6.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000950 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 3.9% | -3.1% | -0.7% |
| 1Y | 8.0% | -18.7% | 3.0% |
Return vs Industry: 000950 exceeded the CN Healthcare industry which returned -18.7% over the past year.
Return vs Market: 000950 exceeded the CN Market which returned 3% over the past year.
Price Volatility
| 000950 volatility | |
|---|---|
| 000950 Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 7.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000950 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000950's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 14,485 | Wei Liu | www.cqphar.com |
C.Q. Pharmaceutical Holding Co., Ltd. distributes pharmaceutical products. The company engages in the research, development, production, and investment for medical device in the pharmaceutical industry. It offers medicines, medical devices, Chinese herbal medicines, health care products, hospital sales, and commercial wholesale, retail chain; terminal distribution; warehousing logistics; and supply chain value-added services.
C.Q. Pharmaceutical Holding Co., Ltd. Fundamentals Summary
| 000950 fundamental statistics | |
|---|---|
| Market cap | CN¥9.78b |
| Earnings (TTM) | CN¥429.57m |
| Revenue (TTM) | CN¥81.43b |
22.8x
P/E Ratio0.1x
P/S RatioIs 000950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000950 income statement (TTM) | |
|---|---|
| Revenue | CN¥81.43b |
| Cost of Revenue | CN¥75.47b |
| Gross Profit | CN¥5.96b |
| Other Expenses | CN¥5.53b |
| Earnings | CN¥429.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 7.31% |
| Net Profit Margin | 0.53% |
| Debt/Equity Ratio | 154.2% |
How did 000950 perform over the long term?
See historical performance and comparison